Olympus Corp
OLY1
Company Profile
Business description
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
Contact
2951 Ishikawacho
Hachioji192-8507
JPNT: +81 333402111
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2026
Employees
29,996
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.50 | 12.40 | 0.14% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,077.23 | 588.64 | 1.21% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,585.40 | 0.34 | 0.00% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,817.03 | 1,042.39 | 1.98% |
| NZX 50 Index | 13,556.87 | 139.70 | 1.04% |
| S&P 500 | 6,875.62 | 78.76 | 1.16% |
| S&P/ASX 200 | 8,848.70 | 12.80 | 0.14% |
| SSE Composite Index | 4,122.11 | 5.17 | 0.13% |